Katie Cox - Guardion Health Chief Officer
| GHSIDelisted Stock | USD 3.29 0.04 1.23% |
Executive
Katie Cox is Chief Officer of Guardion Health Sciences
| Age | 54 |
| Phone | 800 873 5141 |
| Web | https://www.guardionhealth.com |
Guardion Health Management Efficiency
The company has return on total asset (ROA) of (0.1553) % which means that it has lost $0.1553 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5026) %, meaning that it created substantial loss on money invested by shareholders. Guardion Health's management efficiency ratios could be used to measure how well Guardion Health manages its routine affairs as well as how well it operates its assets and liabilities.Guardion Health Sciences currently holds 3.77 M in liabilities. Guardion Health Sciences has a current ratio of 11.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Guardion Health until it has trouble settling it off, either with new capital or with free cash flow. So, Guardion Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guardion Health Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guardion to invest in growth at high rates of return. When we think about Guardion Health's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Lisjak | Cyclo Therapeutics | 50 | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Marilyn Carlson | Evoke Pharma | 76 | |
| Samantha Widdicombe | Biofrontera | N/A | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Advocate Nissimov | Im Cannabis Corp | N/A | |
| Jennifer Henry | Alpha Teknova | N/A | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Damon JD | Alpha Teknova | 54 | |
| John Shulman | Petros Pharmaceuticals | 61 | |
| BA MA | Akanda Corp | 74 | |
| Robert Cavorsi | Organogenesis Holdings | 45 | |
| DMD MD | Evoke Pharma | 76 | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Robert Arnold | Aquestive Therapeutics | N/A | |
| Uri Birenberg | Im Cannabis Corp | 48 | |
| Huang CFA | China Pharma Holdings | N/A | |
| Stephen Wargacki | Aquestive Therapeutics | 46 | |
| Daniel JD | Biofrontera | N/A | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.16 |
Guardion Health Sciences Leadership Team
Elected by the shareholders, the Guardion Health's board of directors comprises two types of representatives: Guardion Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardion. The board's role is to monitor Guardion Health's management team and ensure that shareholders' interests are well served. Guardion Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardion Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Weingarten, Independent Secretary | ||
| Janet Hall, President CEO | ||
| Jeffrey Benjamin, Chief Officer | ||
| Craig Sheehan, Chief Officer | ||
| Bret Scholtes, CEO Pres | ||
| Katie Cox, Chief Officer |
Guardion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Guardion Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | 0.52 % | |||
| Operating Margin | (18.75) % | |||
| Current Valuation | (987.33 K) | |||
| Shares Outstanding | 1.35 M | |||
| Shares Owned By Insiders | 1.30 % | |||
| Shares Owned By Institutions | 21.09 % | |||
| Number Of Shares Shorted | 22.26 K | |||
| Price To Earning | (0.71) X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Guardion Pink Sheet
If you are still planning to invest in Guardion Health Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Guardion Health's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |